Cardiovascular (CV) disease and cancer remain the two most common causes of mortality in developed countries; however, progress in the treatment of malignant diseases significantly improved survival of oncological patients. Similarly, there is an increased number of the patients with malignancy who have a history of CV disease or an increased CV risk. Rates of CV problems from cancer-related therapeutics are high, and cardiotoxicity is the second most common cause of morbidity and mortality in cancer survivors. Therefore, there is a need for the development of an efficient programme to manage the problem of cardiotoxicity with the aim to decrease morbidity and mortality in patients and to improve their quality of life. For this purpose, cardio-oncological clinics should be an essential part of the strategy.

1st Department of Medicine Cardioangiology Charles University Prague Medical Faculty and University HospitalHradec Králové Hradec Králové Czech Republic

See more in PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi: 10.3322/caac.21254. PubMed DOI

Fradley MG, Brown AC, Shields B et al. Developing a comprehensive cardio-oncology program at a cancer institute: the Moffitt Cancer Center Experience. Oncol Rev. 2017;11:340. doi: 10.4081/oncol.2017.340. PubMed DOI PMC

Daher IN, Daigle TR, Bhatia N, Durand JB. The prevention of cardiovascular disease in cancer survivors. Tex Heart Inst J. 2012;39:190–8. PubMed PMC

Miller KD, Siegel RL, Lin CC et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–89. doi: 10.3322/caac.21349. PubMed DOI

Khouri MG, Douglas PS, Mackey JR et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012;126:2749–63. doi: 10.1161/CIRCULATIONAHA.112.100560. PubMed DOI PMC

Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. doi: 10.1093/eurheartj/ehw211. PubMed DOI

Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–54. doi: 10.1161/01.CIR.0000130926.51766CC. PubMed DOI

Ledwidge M, Gallagher J, Conlon C et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66–74. doi: 10.1001/jama.2013.7588. PubMed DOI

Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28:4649–57. doi: 10.1200/JCO.2010.29.9362. PubMed DOI

Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293–305. doi: 10.1093/jnci/djs317. PubMed DOI PMC

Qi WX, Shen Z, Tang LN, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol. 2014;78:748–62. doi: 10.1111/bcp.12387. PubMed DOI PMC

Chen CL, Steingart R. Cardiac disease and heart failure in cancer patients: is our training adequate to provide optimal care? Heart Fail Clin. 2011;7:357–62. doi: 10.1016/j.hfc.2011.03.007. PubMed DOI

Sulpher J, Mathur S, Graham N et al. Clinical experience of patients referred to a multidisciplinary cardiac oncology clinic: an observational study. J Oncol. 2015;2015:671232. doi: 10.1155/2015/671232. PubMed DOI PMC

Albini A, Pennesi G, Donatelli F et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25. doi: 10.1093/jnci/djp440. PubMed DOI PMC

Barac A, Murtagh G, Carver JR et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015;65:2739–46. doi: 10.1016/j.jacc.2015.04.059. PubMed DOI PMC

Methodological Aspects of μLC-MS/MS for Wide-Scale Proteomic Analysis of Anthracycline-Induced Cardiomyopathy

Detection of radiation induced cardiotoxicity: Role of echocardiography and biomarkers